319 related articles for article (PubMed ID: 11298585)
1. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
2. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
3. Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
Navarro JT; Ribera JM; Oriol A; Xicoy B; Mate JL; Sirera G; Lloveras N; Millá F; Feliu E
Int J Hematol; 2007 Nov; 86(4):337-42. PubMed ID: 18055341
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
[TBL] [Abstract][Full Text] [Related]
5. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
[TBL] [Abstract][Full Text] [Related]
6. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
[TBL] [Abstract][Full Text] [Related]
7. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
8. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
[TBL] [Abstract][Full Text] [Related]
9. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
10. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
Tanaka PY; Pracchia LF; Calore EE
Int J Hematol; 2006 Nov; 84(4):337-42. PubMed ID: 17118760
[TBL] [Abstract][Full Text] [Related]
12. Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.
Tulpule A; Espina BM; Pedro Santabarbara AB; Palmer M; Schiflett J; Boswell W; Smith S; Levine AM
Invest New Drugs; 2004 Jan; 22(1):63-8. PubMed ID: 14707495
[TBL] [Abstract][Full Text] [Related]
13. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
15. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Castillo JJ; Echenique IA
Am J Hematol; 2012 Mar; 87(3):330-3. PubMed ID: 22308010
[TBL] [Abstract][Full Text] [Related]
17. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
20. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J
Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]